Puma Biotechnology, Inc.
NASDAQ:PBYIBiotechnology
+$0.16 today
- Market cap
- $373.26M
- Beta
- 1.21
- P/E (TTM)
- 15.4
- EPS (TTM)
- $0.48
Volume 0.45M
Average 0.26M
PBYI Total Non-current Liabilities
All obligations due after more than one year.
Puma Biotechnology, Inc.NASDAQ: PBYI
Total Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total non-current liabilities falls 63.4% from a year ago
Total non-current liabilities stood at $4.55M at the end of Q1 FY2026, down 63.4% from a year earlier and down 3.5% from the prior quarter. Over 3 fiscal years it compounded at -66.3% a year.
Context
- Total non-current liabilities amounted to 2.4% of total assets at the end of Q1 FY2026, down 4.0 pp from a year earlier.
- Total non-current liabilities increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total non-current liabilities keeps falling in the next quarterly balance sheet after a -63.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 4.71M USD
- Year-over-year change
- -81.2%
- 4-year CAGR
- -55.4%
| Period | Period end | Total Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.71M | -81.2% |
| FY2024 | 2024-12-31 | 25.1M | -67.7% |
| FY2023 | 2023-12-31 | 77.7M | -36.8% |
| FY2022 | 2022-12-31 | 122.97M | +2.9% |
| FY2021 | 2021-12-31 | 119.45M | — |
Total Non-current Liabilities vs competitors
How PBYI compares with its peers on the latest reported figures
- Peers report in different currencies, so total non-current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -63.4% is the 8th highest of 10, against a peer median of -21.2%.
- Total non-current liabilities amounts to 2.4% of total assets for PBYI, versus a peer median of 6.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $403.88M USD | +94.2% | +275.6% | 54.2% | |
| Mar 2026 | $100.74M USD | +11.9% | +16.9% | 46.2% | |
| Mar 2026 | $79.19M USD | -38.4% | +65.1% | 34.8% | |
| Sep 2026 | $28.12M USD | -11.2% | -38.3% | 2.7% | |
| Mar 2026 | $14.09M USD | -21.2% | -15.9% | 10.6% | |
| Mar 2026 | CA$7.87M CAD | +5.8% | +1.7% | 96.4% | |
| Mar 2026 | $4.55M USD | -63.4% | -66.3% | 2.4% | |
| Mar 2026 | $3.43M USD | -37.6% | -21.0% | 0.8% | |
NBPNovaBridge Biosciences | Dec 2025 | $384.13K USD | -98.3% | -90.2% | 1.0% |
| Mar 2026 | $320K USD | — | — | 0.1% | |
| Mar 2026 | $0 USD | -100.0% | -63.2% | 0.0% | |
| Peer median (excluding PBYI) | — | -21.2% | -15.9% | 6.7% | |
Competitors are the stored peer set for PBYI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 63.13M | 76.2M | 84.59M | 69.22M | 29.64M |
| Short-term Investments | 18.98M | 4.87M | 11.35M | 31.75M | 67.89M |
| Net Receivables | 32.53M | 42.27M | 48.49M | 32.01M | 53.65M |
| Inventory | 7.11M | 4.53M | 7.08M | 8.72M | 5.52M |
| Other Current Assets | 11.43M | 1.95M | 260K | 3.7M | 4M |
| Total Current Assets | 140.02M | 134.28M | 156.19M | 147.66M | 162.69M |
| Property, Plant & Equipment (Net) | 15.77M | 12.51M | 8.65M | 5.09M | 5.56M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 66.13M | 70.61M | 60.87M | 51.13M | 41.39M |
| Long-term Investments | 0 | 0 | 2.09M | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 7.08M | 3.83M |
| Other Non-current Assets | 4.67M | 4.66M | 2.73M | 2.38M | 2.83M |
| Total Non-current Assets | 86.56M | 87.78M | 74.34M | 65.68M | 53.62M |
| Total Assets | 226.59M | 222.06M | 230.53M | 213.33M | 216.3M |
| Account Payables | 11.17M | 6.44M | 6.89M | 5.51M | 5.06M |
| Short-term Debt | 0 | 0 | 34M | 45.33M | 22.52M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 11.22M | 13.34M | 43.42M | 15.18M | 16.5M |
| Total Current Liabilities | 109.59M | 77.48M | 99.38M | 96.11M | 81.25M |
| Long-term Debt | 97.09M | 98.31M | 65.66M | 21.72M | 4.71M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 6.38M | 12.83M | 5.01M | 1.88M | 0 |
| Total Non-current Liabilities | 119.45M | 122.97M | 77.7M | 25.1M | 4.71M |
| Total Liabilities | 229.03M | 200.45M | 177.09M | 121.21M | 85.96M |
| Common Stock | 4K | 5K | 5K | 5K | 5K |
| Retained Earnings | (1.37B) | (1.37B) | (1.35B) | (1.31B) | (1.28B) |
| Accumulated OCI | (2K) | 0 | (4K) | 6K | 36K |
| Other Stockholders Equity | 0 | (0) | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | (2.45M) | 21.61M | 53.44M | 92.13M | 130.34M |
| Total Debt | 116.64M | 114.28M | 111.49M | 74.08M | 28.55M |
| Net Debt | 53.51M | 38.08M | 26.91M | 4.86M | (1.09M) |
Puma Biotechnology, Inc.
NASDAQ:PBYI
Intrinsic Alpha fair value
Locked
Current Price
$7.22
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.